Table 4.
Survival analysis of prognostic factors for overall survival in 41 PDTCs*.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | p | 95% CI | HR | p | 95% CI | |
| Gender Men vs. Women | 0.87 | 0.733 | (0.39–1.95) | |||
| Age (years) | 1.03 | 0.041 | (1–1.06) | 1.02 | 0.3222 | (0.98–1.06) |
| T3/T4 vs. T1/T2 | 4.01 | 0.024 | (1.2–13.43) | 0.46 | 0.4653 | (0.06–3.69) |
| N1 vs. N0 | 2.8 | 0.098 | (0.83–9.49) | |||
| M1 vs. M0 | 3.62 | 0.024 | (1.19–11.04) | 14.45 | <0.001 | (3.23–64.7) |
| PDL1 Positive vs. Negative | 1.57 | 0.303 | (0.67–3.69) | |||
| PD1 Positive vs. Negative | 0.92 | 0.91 | (0.21–3.96) | |||
| TIGIT Positive vs. Negative | 3.25 | 0.004 | (1.46–7.21) | 1.76 | 0.266 | (0.65–4.79) |
| LAG3 Positive vs. Negative | 1.14 | 0.794 | (0.42–3.08) | |||
| VISTA Strong vs. Others | 3.22 | 0.007 | (1.38–7.53) | 0.68 | 0.5428 | (0.2–2.33) |
| B7H3 Strong vs. Others | 3.57 | 0.007 | (1.41–8.99) | 12.14 | 0.0025 | (2.41–61.14) |
| CTLA4 Positive vs. Negative | 2.04 | 0.08 | (0.92–4.54) | |||
| BTLA Positive vs. Negative | 1.29 | 0.584 | (0.51–3.25) | |||
| TIM3 Strong vs. Others | 4.83 | <0.001 | (2.03–11.51) | 8.25 | <0.001 | (2.4–28.31) |
*Three patients were excluded (two were lost to follow-up and one had followed up in less than 1 month).
The bold values indicates that the p values are less than 0.05, which is considered statistically significant.